253 related articles for article (PubMed ID: 3488859)
1. Inhibition of complement activation by IgG4 antibodies.
van der Zee JS; van Swieten P; Aalberse RC
Clin Exp Immunol; 1986 May; 64(2):415-22. PubMed ID: 3488859
[TBL] [Abstract][Full Text] [Related]
2. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.
Bindon CI; Hale G; Brüggemann M; Waldmann H
J Exp Med; 1988 Jul; 168(1):127-42. PubMed ID: 3260935
[TBL] [Abstract][Full Text] [Related]
3. Activation of the first component of complement, C1, by a monoclonal antibody recognizing the C chain of C1q.
Heinz HP; Burger R; Golan MD; Loos M
J Immunol; 1984 Feb; 132(2):804-8. PubMed ID: 6606678
[TBL] [Abstract][Full Text] [Related]
4. Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q.
Kilchherr E; Schumaker VN; Phillips ML; Curtiss LK
J Immunol; 1986 Jul; 137(1):255-62. PubMed ID: 3486914
[TBL] [Abstract][Full Text] [Related]
5. Study of complement-mediated anaphylaxis in humans. The role of IgG subclasses (IgG1 and/or IgG4) in the complement-activating capacity of immune complexes.
Bergamaschini L; Santangelo T; Faricciotti A; Ciavarella N; Mannucci PM; Agostoni A
J Immunol; 1996 Feb; 156(3):1256-61. PubMed ID: 8558005
[TBL] [Abstract][Full Text] [Related]
6. The distortive mechanism for the activation of complement component C1 supported by studies with a monoclonal antibody against the "arms" of C1q.
Hoekzema R; Martens M; Brouwer MC; Hack CE
Mol Immunol; 1988 May; 25(5):485-94. PubMed ID: 3261834
[TBL] [Abstract][Full Text] [Related]
7. Characterization of C1q by monoclonal antibodies.
Heinz HP; Loos M
Behring Inst Mitt; 1984 Nov; (76):42-58. PubMed ID: 6335397
[TBL] [Abstract][Full Text] [Related]
8. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency.
van der Zee JS; van Swieten P; Aalberse RC
J Immunol; 1986 Dec; 137(11):3566-71. PubMed ID: 3782791
[TBL] [Abstract][Full Text] [Related]
9. Quantification of IgG and IgG4 antibodies to bee venom phospholipase A2 by competitive inhibition in ELISA.
Rieben R; Blaser K
J Immunol Methods; 1989 Apr; 119(1):1-8. PubMed ID: 2708823
[TBL] [Abstract][Full Text] [Related]
10. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions.
Lucisano Valim YM; Lachmann PJ
Clin Exp Immunol; 1991 Apr; 84(1):1-8. PubMed ID: 1707767
[TBL] [Abstract][Full Text] [Related]
11. Complement mediated inhibition of immune precipitation in rheumatoid arthritis: studies on interaction of heat aggregated IgG with IgM rheumatoid factor.
O'Sullivan MM; Amos N; Williams BD
Ann Rheum Dis; 1988 Aug; 47(8):675-80. PubMed ID: 3261968
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal anti-mouse macrophage antibodies recognize the globular portions of C1q, a subcomponent of the first component of complement.
Heinz HP; Dlugonska H; Rüde E; Loos M
J Immunol; 1984 Jul; 133(1):400-4. PubMed ID: 6609989
[TBL] [Abstract][Full Text] [Related]
13. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response.
Aalberse RC; van der Gaag R; van Leeuwen J
J Immunol; 1983 Feb; 130(2):722-6. PubMed ID: 6600252
[TBL] [Abstract][Full Text] [Related]
14. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
Front Immunol; 2018; 9():958. PubMed ID: 29867943
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: inhibition of IgG-mediated complement activation.
Russell MW; Reinholdt J; Kilian M
Eur J Immunol; 1989 Dec; 19(12):2243-9. PubMed ID: 2606139
[TBL] [Abstract][Full Text] [Related]
16. Influence of serum complement and rheumatoid factor on detection of immune complexes by the C1q and monoclonal rheumatoid factor solid-phase assay.
Vanham G; Bloemmen FJ; Ceuppens JL; Stevens EA
J Immunol Methods; 1984 Oct; 73(2):301-11. PubMed ID: 6436384
[TBL] [Abstract][Full Text] [Related]
17. Immune complex mediated activation of the classical complement pathway.
Borsos T
Behring Inst Mitt; 1989 Jul; (84):93-101. PubMed ID: 2478118
[TBL] [Abstract][Full Text] [Related]
18. The role of immune complexes in the activation of the first component of human complement.
Ziccardi RJ
J Immunol; 1984 Jan; 132(1):283-8. PubMed ID: 6317744
[TBL] [Abstract][Full Text] [Related]
19. Prevention of immune precipitation by purified classical pathway complement components.
Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of C1q binding to antigen-antibody complexes by a factor in rheumatoid arthritis serum.
Niven IP; Whaley K
Rheumatol Int; 1986; 6(5):205-8. PubMed ID: 3492025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
